Cargando…
Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo
We estimated the effect of various immunosuppressants (ISs) and metformin (M) to provide theoretical background of optimal therapeutic strategy for de novo colon cancer after liver transplantation (LT). Three colon cancer cell lines (HT29, SW620, and HCT116) were used in in vitro studies. HT29 was a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546956/ https://www.ncbi.nlm.nih.gov/pubmed/28776332 http://dx.doi.org/10.3346/jkms.2017.32.9.1385 |
_version_ | 1783255628996673536 |
---|---|
author | Mussin, Nadiar Oh, Seung Cheol Lee, Kwang-Woong Park, Min Young Seo, Sooin Yi, Nam-Joon Kim, Hyeyoung Yoon, Kyung Chul Ahn, Sung-Woo Kim, Hyo-Sin Hong, Suk Kyun Oh, Dong Kyu Suh, Kyung-Suk |
author_facet | Mussin, Nadiar Oh, Seung Cheol Lee, Kwang-Woong Park, Min Young Seo, Sooin Yi, Nam-Joon Kim, Hyeyoung Yoon, Kyung Chul Ahn, Sung-Woo Kim, Hyo-Sin Hong, Suk Kyun Oh, Dong Kyu Suh, Kyung-Suk |
author_sort | Mussin, Nadiar |
collection | PubMed |
description | We estimated the effect of various immunosuppressants (ISs) and metformin (M) to provide theoretical background of optimal therapeutic strategy for de novo colon cancer after liver transplantation (LT). Three colon cancer cell lines (HT29, SW620, and HCT116) were used in in vitro studies. HT29 was also used in BALB/c-nude mice animal models. Following groups were used in both in vitro and in vivo studies: sirolimus (S), tacrolimus (T), cyclosporin A (CsA), M, metformin/sirolimus (Met/S), metformin/tacrolimus (Met/T), and metformin/cyclosporin A (Met/CsA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed and western blot analyses were performed for mTOR pathway proteins, apoptosis proteins, and epithelial-mesenchymal-transition (EMT) proteins. Tumor volume was measured for 4 weeks after inoculation. MTT-assay revealed significant cell viability inhibition in all 3 colon cancer cell lines in groups of S, M, and Met/S. Of note, group Met/S showed synergistic effect compare to M or S group. Western blot analysis showed significant low levels of all investigated proteins in groups of S and Met/S in both in vitro and in vivo experiment. Tumor growth was significantly inhibited only in the Met/S group. Combination of Met and S showed the most potent inhibition in all colon cancer cell lines. This finding might have application for de novo colon cancer. |
format | Online Article Text |
id | pubmed-5546956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-55469562017-09-01 Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo Mussin, Nadiar Oh, Seung Cheol Lee, Kwang-Woong Park, Min Young Seo, Sooin Yi, Nam-Joon Kim, Hyeyoung Yoon, Kyung Chul Ahn, Sung-Woo Kim, Hyo-Sin Hong, Suk Kyun Oh, Dong Kyu Suh, Kyung-Suk J Korean Med Sci Original Article We estimated the effect of various immunosuppressants (ISs) and metformin (M) to provide theoretical background of optimal therapeutic strategy for de novo colon cancer after liver transplantation (LT). Three colon cancer cell lines (HT29, SW620, and HCT116) were used in in vitro studies. HT29 was also used in BALB/c-nude mice animal models. Following groups were used in both in vitro and in vivo studies: sirolimus (S), tacrolimus (T), cyclosporin A (CsA), M, metformin/sirolimus (Met/S), metformin/tacrolimus (Met/T), and metformin/cyclosporin A (Met/CsA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed and western blot analyses were performed for mTOR pathway proteins, apoptosis proteins, and epithelial-mesenchymal-transition (EMT) proteins. Tumor volume was measured for 4 weeks after inoculation. MTT-assay revealed significant cell viability inhibition in all 3 colon cancer cell lines in groups of S, M, and Met/S. Of note, group Met/S showed synergistic effect compare to M or S group. Western blot analysis showed significant low levels of all investigated proteins in groups of S and Met/S in both in vitro and in vivo experiment. Tumor growth was significantly inhibited only in the Met/S group. Combination of Met and S showed the most potent inhibition in all colon cancer cell lines. This finding might have application for de novo colon cancer. The Korean Academy of Medical Sciences 2017-09 2017-07-28 /pmc/articles/PMC5546956/ /pubmed/28776332 http://dx.doi.org/10.3346/jkms.2017.32.9.1385 Text en © 2017 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Mussin, Nadiar Oh, Seung Cheol Lee, Kwang-Woong Park, Min Young Seo, Sooin Yi, Nam-Joon Kim, Hyeyoung Yoon, Kyung Chul Ahn, Sung-Woo Kim, Hyo-Sin Hong, Suk Kyun Oh, Dong Kyu Suh, Kyung-Suk Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo |
title | Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo |
title_full | Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo |
title_fullStr | Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo |
title_full_unstemmed | Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo |
title_short | Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo |
title_sort | sirolimus and metformin synergistically inhibits colon cancer in vitro and in vivo |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546956/ https://www.ncbi.nlm.nih.gov/pubmed/28776332 http://dx.doi.org/10.3346/jkms.2017.32.9.1385 |
work_keys_str_mv | AT mussinnadiar sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT ohseungcheol sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT leekwangwoong sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT parkminyoung sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT seosooin sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT yinamjoon sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT kimhyeyoung sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT yoonkyungchul sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT ahnsungwoo sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT kimhyosin sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT hongsukkyun sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT ohdongkyu sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo AT suhkyungsuk sirolimusandmetforminsynergisticallyinhibitscoloncancerinvitroandinvivo |